Kyntra Bio Inc (KYNB) Stock Price, Quote & News

Company Profile

Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers. It is also developing Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment...

Industry: Biotechnology

Sector: Healthcare

Phone: 415 978 1200

Fax: 415 978 1902

Website: www.kyntrabio.com

Address:

350 Bay Street, Suite 100 #6009, San Francisco, United States

ARKADIY_PAROVOZOV May. 13 at 8:29 AM

$KYNB H.C. Wainwright reiterated their Buy rating on Kyntra Bio (KYNB) with a $43 price target after the Q1 results. Analyst continues to highlight progress with FG-3246 and the strong cash position. https://www.tipranks.com/news/ratings/kyntra-advancing-oncology-and-lr-mds-programs-with-strong-cash-position-buy-rating-and-43-price-target-reiterated-ratings-news?utm_source=edition.cnn.com&utm_medium=referral

1 · Reply

Estimize May. 12 at 8:00 PM

Wall St is expecting -3.27 EPS for $KYNB Q2 [Reporting 08/10 AMC] http://www.estimize.com/intro/kynb?chart=historical&metric_name=eps&utm_c

0 · Reply

StocktwitsEarnings May. 11 at 9:33 PM

$KYNB Q1 '26 Earnings Results & Recap Kyntra Bio anticipates interim analysis for the FG-3246 Phase 2 trial in 4Q 2026 and plans to initiate the pivotal Phase 3 roxadustat trial in 2H 2026. Kyntra Bio expects its cash runway into 2028.

0 · Reply

StocktwitsEarnings May. 11 at 8:11 PM

$KYNB Q1 '26 Earnings Results & Recap • Reported GAAP EPS of -$3.76 up 6.00% YoY • Reported revenue of $3.74M up 36.47% YoY • Kyntra Bio expects its $100.3M in cash, cash equivalents, investments, and accounts receivable to fund operating plans into 2028, and anticipates Roxadustat Phase 3 trial initiation in the second half of 2026.

0 · Reply

MaxMiamiFl May. 11 at 8:03 PM

$KYNB per chat GPT...mention of need for cash is likey to be announced. If so, wait for a strong drop.

1 · Reply

MaxMiamiFl May. 11 at 3:32 PM

$KYNB Lets see how it goes today. Not that i think anything meaningful will be mentioned.

0 · Reply

ARKADIY_PAROVOZOV May. 8 at 11:57 AM

$KYNB UBS Asset Management significantly increased its position in Kyntra Bio (KYNB), adding 18,159 shares in May 2026. The fund now holds 27,591 shares, signaling growing institutional interest in the company. https://fintel.io/so/us/kynb/ubs

2 · Reply

ARKADIY_PAROVOZOV May. 8 at 8:35 AM

$KYNB Platinum Pharmaceuticals has launched Oxyrena™ (Roxadustat) in Pakistan, expanding global access to the drug for anemia treatment. While this launch has limited direct impact on Kyntra Bio (which holds rights only in North America), it demonstrates that Roxadustat continues to gain commercial traction and expand worldwide through its various partners. https://www.linkedin.com/posts/jalbani-g-abbas-1b747236_its-an-amazing-launch-of-platinum-activity-7458103946755063808-HwJb

0 · Reply

ARKADIY_PAROVOZOV May. 7 at 9:26 AM

$KYNB New academic thesis on Roxadustat in Alzheimer’s disease models just deposited: "Efecto de Roxadustat en Modelos de Enfermedad de Alzheimer" by Nicolás Capelo Carrasco (University of Seville) Interesting preclinical exploration of HIF stabilization beyond anemia. https://doctorado.us.es/estudios/tesis-doctoral/tesis-deposito

0 · Reply

ARKADIY_PAROVOZOV May. 5 at 7:36 AM

$KYNB Kyntra Bio will report Q1 2026 Financial Results on May 11, 2026 (after market close), followed by a conference call at 5:00 PM ET. https://investor.kyntrabio.com/news-releases/news-release-details/kyntra-bio-report-first-quarter-2026-financial-results

0 · Reply

Kyntra Bio Earnings Call Transcript: Q1 2026

May 11, 2026, 4:05 PM EDT - 1 day ago

Kyntra Bio Reports First Quarter 2026 Financial Results and Provides Business Update

May 4, 2026, 4:05 PM EDT - 8 days ago

Kyntra Bio to Report First Quarter 2026 Financial Results

Apr 13, 2026, 1:30 PM EDT - 4 weeks ago

Kyntra Bio Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 8, 2026, 4:05 PM EDT - 4 weeks ago

Kyntra Bio to Present at the 25th Annual Needham Virtual Healthcare Conference

Mar 16, 2026, 5:00 PM EDT - 2 months ago

Kyntra Bio Earnings Call Transcript: Q4 2025

Mar 16, 2026, 4:02 PM EDT - 2 months ago

Kyntra Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Mar 11, 2026, 2:20 PM EDT - 2 months ago

Kyntra Bio Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 7:00 AM EDT - 2 months ago

Kyntra Bio to Report Fourth Quarter and Full Year 2025 Financial Results

Feb 26, 2026, 2:40 PM EST - 2 months ago

Kyntra Bio Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

2026-02-23T22:16:08.000Z - 2 months ago

Kyntra Bio announces positive data from Phase 1b/2 study of FG-3246

Feb 23, 2026, 5:10 PM EST - 2 months ago

Kyntra Bio Announces Positive Data from the Investigator-Sponsored Phase 1b/2 Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer to Be Presented at ASCO GU 2026

Feb 17, 2026, 4:05 PM EST - 3 months ago

Kyntra Bio to Participate in Upcoming Investor Conferences

Jan 7, 2026, 7:30 AM EST - 4 months ago

FibroGen Rebrands as Kyntra Bio to Reflect a New Era of Focus and Momentum

Nov 10, 2025, 5:00 PM EST - 6 months ago

Kyntra Bio Earnings Call Transcript: Q3 2025

Nov 3, 2025, 4:02 PM EST - 6 months ago

FibroGen to Report Third Quarter 2025 Financial Results

Sep 24, 2025, 7:00 AM EDT - 8 months ago

FibroGen Initiates Phase 2 Monotherapy Trial of FG-3246, a First-in-Class CD46 Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer

Sep 9, 2025, 12:00 PM EDT - 8 months ago

Kyntra Bio Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Aug 27, 2025, 4:02 PM EDT - 9 months ago

FibroGen to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 18, 2025, 7:00 AM EDT - 9 months ago

FibroGen Announces Approval of Sale of FibroGen China to AstraZeneca by the China State Administration for Market Regulation

Aug 11, 2025, 5:00 PM EDT - 9 months ago

Kyntra Bio Earnings Call Transcript: Q2 2025

Aug 11, 2025, 4:02 PM EDT - 9 months ago

FibroGen Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 4, 2025, 4:02 PM EDT - 10 months ago

FibroGen to Report Second Quarter 2025 Financial Results

Jun 12, 2025, 4:02 PM EDT - 11 months ago

FibroGen Announces 1-for-25 Reverse Stock Split

Jun 9, 2025, 4:02 PM EDT - 1 year ago

FibroGen Appoints Michael Kauffman, M.D., Ph.D. to its Board of Directors

May 12, 2025, 5:00 PM EDT - 1 year ago

Kyntra Bio Earnings Call Transcript: Q1 2025

May 12, 2025, 4:02 PM EDT - 1 year ago

FibroGen Reports First Quarter 2025 Financial Results and Provides Business Update

May 8, 2025, 4:24 AM EDT - 1 year ago

Duchenne Muscular Dystrophy (DMD) Pipeline Insight Report 2025, Featuring Analysis of Vamorolone (Santhera), Givinostat (Italfarmaco), and Pamrevlumab (Fibrogen)

May 5, 2025, 4:05 PM EDT - 1 year ago

FibroGen to Report First Quarter 2025 Financial Results

Apr 2, 2025, 4:05 PM EDT - 1 year ago

FibroGen to Participate in the 24th Annual Needham Virtual Healthcare Conference

Mar 17, 2025, 5:00 PM EDT - 1 year ago

Kyntra Bio Earnings Call Transcript: Q4 2024

Mar 17, 2025, 4:05 PM EDT - 1 year ago

FibroGen Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 3, 2025, 4:45 PM EST - 1 year ago

FibroGen to Report Fourth Quarter and Full Year 2024 Financial Results

Feb 20, 2025, 8:30 AM EST - 1 year ago

Kyntra Bio Transcript: Status Update

Feb 20, 2025, 6:40 AM EST - 1 year ago

FibroGen sells China unit to AstraZeneca in deal worth $160 million

AZN

Feb 20, 2025, 6:30 AM EST - 1 year ago

FibroGen Announces the Sale of FibroGen China to AstraZeneca for Approximately $160 Million

Dec 16, 2024, 8:05 AM EST - 1 year ago

FibroGen Appoints David DeLucia as Chief Financial Officer

Nov 12, 2024, 5:00 PM EST - 1 year ago

Kyntra Bio Earnings Call Transcript: Q3 2024

Nov 12, 2024, 4:05 PM EST - 1 year ago

FibroGen Reports Third Quarter 2024 Financial Results

Nov 4, 2024, 4:05 PM EST - 1 year ago

FibroGen to Report Third Quarter 2024 Financial Results

Sep 10, 2024, 3:00 PM EDT - 1 year ago

Kyntra Bio Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Aug 6, 2024, 5:00 PM EDT - 1 year ago

Kyntra Bio Earnings Call Transcript: Q2 2024

Jul 30, 2024, 4:07 PM EDT - 1 year ago

FibroGen to Report Second Quarter 2024 Financial Results

Jun 10, 2024, 10:00 AM EDT - 2 years ago

Kyntra Bio Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

Jun 3, 2024, 4:05 PM EDT - 2 years ago

FibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate FibroGen's Immuno-Oncology Assets, FG-3165 (anti-Galectin 9) and FG-3175 (anti-CCR8), in Combination with LIBTAYO® in Upcoming Clinical Trials

Jun 3, 2024, 4:02 PM EDT - 2 years ago

FibroGen Announces FDA Clearance of Investigational New Drug Application for FG-3165, a Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors

May 23, 2024, 5:05 PM EDT - 2 years ago

FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) at the 2024 American Society of Clinical Oncology

May 20, 2024, 1:30 PM EDT - 2 years ago

Kyntra Bio Transcript: H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

May 7, 2024, 7:00 AM EDT - 2 years ago

FibroGen to Participate in Upcoming Investor Conferences

May 6, 2024, 5:00 PM EDT - 2 years ago

Kyntra Bio Earnings Call Transcript: Q1 2024

May 6, 2024, 4:02 PM EDT - 2 years ago

FibroGen Reports First Quarter 2024 Financial Results

Apr 29, 2024, 7:00 AM EDT - 2 years ago

FibroGen to Report First Quarter 2024 Financial Results

Apr 24, 2024, 4:02 PM EDT - 2 years ago

FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology A

Apr 9, 2024, 3:00 PM EDT - 2 years ago

Kyntra Bio Transcript: 23rd Annual Needham Virtual Healthcare Conference

Apr 2, 2024, 5:46 PM EDT - 2 years ago

FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer

Mar 26, 2024, 7:00 AM EDT - 2 years ago

FibroGen to Present at 23rd Annual Needham Virtual Healthcare Conference

Mar 11, 2024, 7:00 AM EDT - 2 years ago

FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer

Feb 26, 2024, 5:00 PM EST - 2 years ago

Kyntra Bio Earnings Call Transcript: Q4 2023

Feb 26, 2024, 4:18 PM EST - 2 years ago

FibroGen regains rights to anemia drug from AstraZeneca

AZN

Feb 26, 2024, 4:06 PM EST - 2 years ago

FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results

Feb 26, 2024, 4:05 PM EST - 2 years ago

FibroGen Regains All Rights to Roxadustat from AstraZeneca in the United States and Other AstraZeneca Territories, Except China and South Korea

Feb 20, 2024, 7:00 AM EST - 2 years ago

FibroGen to Report Fourth Quarter and Full Year 2023 Financial Results

Feb 13, 2024, 10:30 AM EST - 2 years ago

Kyntra Bio Transcript: Study Update

Feb 5, 2024, 7:00 AM EST - 2 years ago

FibroGen To Host Part I of Virtual KOL Investor Event Series to Review Pamrevlumab Clinical Program in Pancreatic Cancer on February 13, 2024

Jan 25, 2024, 7:00 AM EST - 2 years ago

FibroGen Announces Completion of the Pamrevlumab Arm in Precision Promise, Pancreatic Cancer Action Network's Phase 2/3 Adaptive Platform Trial for Metastatic Pancreatic Cancer

Dec 9, 2023, 5:02 PM EST - 2 years ago

FibroGen Presents Data from Phase 3 MATTERHORN Trial of Roxadustat in Patients with Anemia of Lower Risk Transfusion-Dependent Myelodysplastic Syndromes at American Society of Hematology Annual Meeting

Nov 6, 2023, 5:00 PM EST - 2 years ago

Kyntra Bio Earnings Call Transcript: Q3 2023

Nov 6, 2023, 4:01 PM EST - 2 years ago

FibroGen Reports Third Quarter 2023 Financial Results

Oct 23, 2023, 7:00 AM EDT - 2 years ago

FibroGen to Report Third Quarter 2023 Financial Results

ARKADIY_PAROVOZOV May. 13 at 8:29 AM

1 · Reply

Estimize May. 12 at 8:00 PM

Wall St is expecting -3.27 EPS for $KYNB Q2 [Reporting 08/10 AMC] http://www.estimize.com/intro/kynb?chart=historical&metric_name=eps&utm_c

0 · Reply

StocktwitsEarnings May. 11 at 9:33 PM

0 · Reply

StocktwitsEarnings May. 11 at 8:11 PM

0 · Reply

MaxMiamiFl May. 11 at 8:03 PM

$KYNB per chat GPT...mention of need for cash is likey to be announced. If so, wait for a strong drop.

1 · Reply

MaxMiamiFl May. 11 at 3:32 PM

$KYNB Lets see how it goes today. Not that i think anything meaningful will be mentioned.

0 · Reply

ARKADIY_PAROVOZOV May. 8 at 11:57 AM

2 · Reply

ARKADIY_PAROVOZOV May. 8 at 8:35 AM

0 · Reply

ARKADIY_PAROVOZOV May. 7 at 9:26 AM

0 · Reply

ARKADIY_PAROVOZOV May. 5 at 7:36 AM

0 · Reply

ARKADIY_PAROVOZOV May. 4 at 2:37 PM

$KYNB This directly contradicts the old safety concerns (which were the main reason for the FDA's rejection of the CKD). https://pmc.ncbi.nlm.nih.gov/articles/PMC13112930/

1 · Reply

ARKADIY_PAROVOZOV May. 4 at 2:34 PM

$KYNB New study published in Therapeutic Apheresis and Dialysis (April 2026) found that CKD patients on hemodialysis treated with roxadustat had significantly lower risk of both bleeding (OR 0.376) and thromboembolic events (OR 0.287) compared to non-roxadustat users. Positive real-world safety signal for the HIF-PHI class. https://pmc.ncbi.nlm.nih.gov/articles/PMC13112930/

0 · Reply

ARKADIY_PAROVOZOV May. 4 at 9:20 AM

$KYNB New review article in Kidney International (2026) by HIF expert Volker H. Haase discusses the mechanisms, clinical challenges, and safety profile of HIF-PHI inhibitors, including roxadustat. A balanced overview highlighting both the potential and important safety considerations for the class. https://www.sciencedirect.com/science/article/pii/S0272638626000089 Useful scientific context ahead of Kyntra’s Phase 3 MDS program.

0 · Reply

BillionerOfKing May. 1 at 2:49 AM

$KYNB Current Stock Price: $7.27

0 · Reply

VioletSpencer1 Apr. 30 at 6:01 PM

$KYNB microcap style tape, small volume can move it so risk stays high

1 · Reply

ARKADIY_PAROVOZOV Apr. 30 at 11:03 AM

$KYNB Kyntra Bio’s FG-3246 (CD46-targeted ADC) Phase 2 dose optimization trial in metastatic castration-resistant prostate cancer is actively recruiting at Yale Medicine. The trial page was updated today (April 30, 2026), confirming the study is ongoing under Dr. Daniel Petrylak. https://www.yalemedicine.org/clinical-trials/fgcl-3246-112-a-study-of-fg-3246-in-participants-with-metastatic-castration-resistant-prostate-canc Steady progress on the ADC program. 🚀

1 · Reply

ARKADIY_PAROVOZOV Apr. 28 at 1:46 PM

$KYNB Roxadustat (Evrenzo) has been officially added to the UK NHS Drug Tariff for the first time. Starting May 2026, the 20/50/70/100 mg tablets are now listed for full NHS reimbursement in England and Wales. https://www.nhsbsa.nhs.uk/sites/default/files/2026-04/Drug%20Tariff%20Part%20II%20May%202026.pdf Another positive step for roxadustat adoption.

1 · Reply

ARKADIY_PAROVOZOV Apr. 28 at 11:37 AM

$KYNB Kyntra Bio filed its Definitive Proxy Statement (DEF 14A) with the SEC today. Annual shareholder meeting is scheduled for June 12, 2026 (virtual), including the election of director Michael Kauffman, M.D., Ph.D. Full filing here: https://www.sec.gov/Archives/edgar/data/0000921299/000119312526182044/kynb-20260427.htm

0 · Reply

ARKADIY_PAROVOZOV Apr. 28 at 10:19 AM

$KYNB New preclinical study published in Hans Journal of Biomedicine (2026) shows that roxadustat significantly reduces oxidative stress and apoptosis in a rat model of diabetic nephropathy through HIF-1α activation. Another interesting “multi-tasker” signal for roxadustat in diabetic kidney disease. https://www.hanspub.org/journal/paperinformation?paperid=140085 Scientific momentum continues to build! 🚀

0 · Reply

MaxMiamiFl Apr. 27 at 6:35 PM

$KYNB I grabbed 350 xtra Shares today for $7.02

0 · Reply

ARKADIY_PAROVOZOV Apr. 27 at 12:14 PM

$KYNB New practical review on anemia management in CKD from a nephrology blog highlights roxadustat as a promising oral HIF-PHI alternative to traditional ESA therapy, particularly in patients with ESA hyporesponsiveness or those preferring oral treatment. https://nephro.blog/anemie/ Continued real-world clinical discussion around roxadustat in Europe.

0 · Reply

ARKADIY_PAROVOZOV Apr. 27 at 6:43 AM

$KYNB New clinical study published in Signal Transduction and Targeted Therapy (Nature, April 21, 2026): Roxadustat + sirolimus combination in 82 patients with acquired pure red cell aplasia (aPRCA) delivered impressive results: Overall response rate: 93% at 6 months Complete response rate: 77.5% Transfusion independence achieved in 89.5% of patients https://www.nature.com/articles/s41392-026-02635-2 Strong real-world signal for roxadustat in hard-to-treat anemias.

0 · Reply

Market Cap	27.53M
Revenue (ttm)	6.44M
Net Income (ttm)	183.45M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	2,848.60%
Debt to Equity Ratio	0.00

Volume	12,900
Avg Vol	20,838
Day's Range	N/A - N/A
Shares Out	4.05M
Stochastic %K	84%
Beta	1.03
Analysts	Sell
Price Target	$43.00